This article is more than 5 years old. Information may no longer be current.
Phylloquinone improved glycemic status in women with prediabetes before menopause
Premenopausal women with prediabetes showed improved glycemic status with supplements of phylloquinone, or vitamin K1, according to research published in the Journal of Diabetes & Metabolic Disorders.
“Although this study could not provide the underlying mechanism, we speculate that vitamin K1 supplementation could modulate glycemic status by mechanisms other than total osteocalcin and adiponectin,” the researchers wrote.
Hamid Rasekhi, PhD, of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, and colleagues assigned 82 women aged 22 to 45 years (BMI, 18.5-30 kg/m2) with diagnosed prediabetes to take either vitamin K1 supplements (n=39) or placebo (n=43).
Over four weeks, the treatment group received 1,000 mcg phylloquinone in a single pearl softgel capsule, and the placebo group a placebo capsule, daily. Blood samples were collected at baseline and at the end of the study to quantify osteocalcin, adiponectin, leptin and relevant variables.
Compared with placebo, phylloquinone supplementation increased serum adiponectin concentration (1.24 ± 1.9 vs. −0.27 ± 1.08 mcg/ml) and did not change total osteocalcin (0.5 ± 4.11 vs. 0.13 ± 1.85 ng/ml; P=.61) and leptin (−0.29 ± 8.23 vs. −1.15 ± 5.25 ng/ml; P=.92).
Based on analysis of covariance, adjustments for total osteocalcin and adiponectin did not affect the relationship between glycemic status and related variables.
Disclosure: This work was supported by a grant from the Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences.